Rachel Ellingson, a director at BioLife Solutions Inc., has reported the sale of 57,995 shares of the company following its recent merger with Repligen Corporation. This transaction, filed with the SEC on October 8, 2026, is significant as it marks a notable change in ownership in the electromedical sector.
Background
BioLife Solutions Inc. operates within the electromedical and electrotherapeutic apparatus industry. The company is known for its innovative solutions in the preservation and storage of cells and tissues. The SEC filing, dated October 8, 2026, reveals that Ellingson sold her shares on October 6, 2026, coinciding with the completion of the merger between BioLife Solutions and Repligen Corporation.
What the Filing Says
The filing indicates that Ellingson disposed of 57,995 shares of common stock in BioLife Solutions. The transaction was categorized under code 'D', indicating a disposition of shares. Notably, the filing states, "Reflects the disposition of shares of common stock... in connection with the consummation on October 6, 2026 of the merger..." This merger involved the conversion of each outstanding share of BioLife into cash and shares of Repligen common stock, as per the terms of the merger agreement.
Impact
This transaction may affect various stakeholders, including shareholders of BioLife Solutions and Repligen Corporation. As the company integrates its operations following the merger, the market dynamics within the electromedical industry could see significant changes. Competitors in this space may need to adjust their strategies in response to the consolidation.
What's Next
The filing does not say what happens next.